Liang N Wang

US Patent:

6387920, May 14, 2002

Filed:

Apr 11, 2001

Appl. No.:

09/833392

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Jennifer C. Moore - Emeryville CA
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA
Rajinder Singh - San Francisco CA
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 3144

US Classification:

514293, 546 83

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6727273, Apr 27, 2004

Filed:

Sep 18, 2001

Appl. No.:

09/954039

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Beata Krywult - Armadale, AU
Rajinder Singh - San Francisco CA
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 31416

US Classification:

514406, 5483591

Abstract:

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6743815, Jun 1, 2004

Filed:

Apr 25, 2002

Appl. No.:

10/134302

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Jennifer C. Moore - Emeryville CA
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA
Rajinder Singh - San Francisco CA
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 3142

US Classification:

514378, 548240

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6869969, Mar 22, 2005

Filed:

Nov 13, 2003

Appl. No.:

10/713621

Inventors:

Verena D. Huebner - Benicia CA, US
Xiaodong Lin - Walnut Creek CA, US
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ, US
Manoj Desai - Pleasant Hill CA, US
Jennifer C. Moore - Emeryville CA, US
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA, US
Rajinder Singh - San Francisco CA, US
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K031/42
C07D261/02
C07D261/06

US Classification:

514378, 548240, 548247

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

US Patent:

RE39708, Jun 26, 2007

Filed:

Jan 13, 2004

Appl. No.:

10/757347

Inventors:

Verena D. Huebner - Benicia CA, US
Xiaodong Lin - Hercules CA, US
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ, US
Manoj C. Desai - Pleasant Hill CA, US
Beata Krywult - Oakleigh East, AU
Rajinder Singh - Belmont CA, US
Liang Wang - Lafayette CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 31/415
A61P 19/10
C07D 231/12

US Classification:

514406, 5483771

Abstract:

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

US Patent:

7761379, Jul 20, 2010

Filed:

Jun 26, 2006

Appl. No.:

11/475722

Inventors:

Scott M. Zoldi - San Diego CA, US
Liang Wang - San Diego CA, US
Li Sun - San Diego CA, US
Steven G. Wu - San Diego CA, US

Assignee:

Fair Isaac Corporation - Minneapolis MN

International Classification:

G06Q 40/00

US Classification:

705 44

Abstract:

A system and method for managing mass compromise of financial transaction devices is disclosed. A method includes maintaining a summary of a transaction history for a financial transaction device, and forming a device history profile based on the transaction history, the device history profile including predictive variables indicative of fraud associated with the financial transaction device. A method further includes generating a fraud score based on the predictive variables, the fraud score representing a likelihood that the financial transaction device is compromised will be used fraudulently.

US Patent:

7945515, May 17, 2011

Filed:

Jul 16, 2010

Appl. No.:

12/838303

Inventors:

Scott M. Zoldi - San Diego CA, US
Liang Wang - San Diego CA, US
Li Sun - San Diego CA, US
Steven G. Wu - San Diego CA, US

Assignee:

Fair Isaac Corporation - Minneapolis MN

International Classification:

G06Q 40/00

US Classification:

705 44

Abstract:

A system and method for managing mass compromise of financial transaction devices is disclosed. A method includes maintaining a summary of a transaction history for a financial transaction device, and forming a device history profile based on the transaction history, the device history profile including predictive variables indicative of fraud associated with the financial transaction device. A method further includes generating a fraud score based on the predictive variables, the fraud score representing a likelihood that the financial transaction device is compromised will be used fraudulently.

US Patent:

20040077701, Apr 22, 2004

Filed:

Jun 12, 2003

Appl. No.:

10/461914

Inventors:

Verena Huebner - Benicia CA, US
Xiaodong Lin - Walnut Creek CA, US
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ, US
Manoj Desai - Pleasant Hill CA, US
Beata Krywult - Armadale, AU
Rajinder Singh - San Francisco CA, US
Liang Wang - Lafayette CA, US

Assignee:

CHIRON CORPORATION - Emeryville CA

International Classification:

C07D231/02
C07D231/08
A61K031/415

US Classification:

514/406000, 548/364100, 548/366100, 548/367400

Abstract:

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.